The phase III KEYNOTE-756 and CheckMate 7FL studies demonstrated that combining ICIs with neoadjuvant chemotherapy significantly improved the pathological complete response (pCR) rate in ER+/HER2- breast cancer patients18, 19. This evidence concerns the gene ESR1 and breast carcinoma.